Literature DB >> 16095113

Inflammatory changes of hip synovial structures in polymyalgia rheumatica.

F Cantini1, L Niccoli, C Nannini, A Padula, I Olivieri, L Boiardi, C Salvarani.   

Abstract

OBJECTIVE: To investigate the hip inflammatory lesions and to evaluate the accuracy of clinical examination compared to magnetic resonance imaging (MRI) in patients with polymyalgia rheumatica (PMR) with pelvic girdle symptoms. Secondary end-point was to evaluate the sensitivity and specificity of ultrasonography (US) compared to MRI in the assessment of hip lesions.
METHODS: Case-control study of 20 consecutive PMR patients and 40 controls with different rheumatic conditions. Both groups were clinically assessed for the presence of hip synovitis, trochanteric, iliopsoas and ischiogluteal bursitis. Hip MRI was performed in all case-patients and in 10 controls. Both groups were examined by US. An additional group of 10 healthy controls was examined by hip US.
RESULTS: Both MRI and US detected trochanteric bursitis in 100% of PMR patients, bilateral in 18/20 (90%), and in 12/40 (30%) controls (p < 0.001). Hip synovitis was detected in 17/20 (85%) by MRI and in 9/20 (45%) by US (p < 0.02) in case-patients and in 18/40 (45%) controls. In PMR, MRI and US showed iliopsoas bursitis in 10/20 (50%) and 6/20 (30%) and ischiogluteal bursitis in 5/20 (25%) and 4/20 (20%) with no differences compared to controls. Clinical examination showed a good accuracy for hip synovitis, trochanteric and ischiogluteal bursitis, while it overestimated the presence of iliopsoas bursitis. US was less sensitive than MRI for the detection of hip synovitis and iliopsoas bursitis (53% and 60%).
CONCLUSION: Trochanteric bursitis represents the most frequent hip lesion in PMR. A careful physical examination allows to detect all inflammatory lesions excluding iliopsoas bursitis. US is less sensitive than MRI in the assessment of hip synovitis and iliopsoas bursitis.

Entities:  

Mesh:

Year:  2005        PMID: 16095113

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  18 in total

Review 1.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 2.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 3.  Diagnosis and treatment of giant cell arteritis.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Michele Bertoni; Carlo Salvarani
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 4.  Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica.

Authors:  Thomas Nothnagl; Burkhard F Leeb
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

5.  [Polymyalgia rheumatica in daily routine practice].

Authors:  M Talke; W A Schmidt
Journal:  Z Rheumatol       Date:  2014-06       Impact factor: 1.372

Review 6.  Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-02       Impact factor: 5.346

7.  Reliability exercise for the polymyalgia rheumatica classification criteria study: the oranjewoud ultrasound substudy.

Authors:  Alexander K Scheel; Eric L Matteson; Bhaskar Dasgupta; George A W Bruyn; Sarah Ohrndorf; Carola Werner; Wolfgang A Schmidt
Journal:  Int J Rheumatol       Date:  2009-06-14

8.  [Polymyalgia rheumatica].

Authors:  W A Schmidt
Journal:  Z Rheumatol       Date:  2013-02       Impact factor: 1.372

Review 9.  [Myalgia in polymyalgia rheumatica, temporal arteritis and other vasculitides].

Authors:  W A Schmidt
Journal:  Z Rheumatol       Date:  2009-08       Impact factor: 1.372

10.  Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial.

Authors:  Frederik Kreiner; Henrik Galbo
Journal:  Arthritis Res Ther       Date:  2010-09-20       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.